Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Combination Overcomes Breast Cancer Resistance… >
Combination Overcomes Breast Cancer Resistance to Herceptin

Published: March 14, 2011.
By University of Texas M. D. Anderson Cancer Center
http://www.mdanderson.org

HOUSTON - Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five different molecular pathways, each of which can resist, said senior author Dihua Yu, M.D., Ph.D., professor in MD Anderson's Department of Molecular and Cellular Oncology.

"Scientists have identified so many ways by which a tumor resists Herceptin that it raises an important issue for treatment," Yu said. "Will we have to give patients six drugs or 10 drugs to block them all? The side effects would be awful. Two pills are better. This combination is a promising therapy for those with Herceptin-resistant breast cancer."

Working in cell lines, mouse models of breast cancer and checking their work in human tumor samples, Yu and colleagues identified SRC, a known cancer-promoting protein, as the crucial common downstream component of multiple resistance pathways.

Saracatinib is an SRC inhibitor, thwarting that protein and allowing Herceptin to work again in tumors that have a high amount of the HER2 protein.

Only about 26 percent of women with HER2-positive breast cancer respond to Herceptin as single therapy. Between 40 and 60 percent respond to the drug when combined with other chemotherapy.

Combination is ready for clinical trials

Yu said saracatinib has been tested in phase I and phase II clinical trials as a single treatment against late-stage cancers. It has a favorable side effects profile.

"It didn't work as a single agent, but very few drugs work by themselves against late stage disease," Yu said. "Our experiments confirmed its lack of efficacy as a sole treatment. But combined with Herceptin, it's beautiful."

Another SRC inhibitor, dasatinib, has been approved by the U.S. Food and Drug Administration as an anti-cancer drug, but it has harsher side effects, said Siyuan Zhang, Ph.D., a postdoctoral fellow in Yu's lab and the paper's first author.

A tumor-suppressor's job

In 2004, Yu's lab discovered that loss of the tumor-suppressing gene known as PTEN led to Herceptin-resistant tumors. PTEN is a phosphotase - a protein whose function is to strip phosphate chemical groups off of other molecules.

PTEN has two components, one to remove phosphate groups from lipids, and another to remove them from proteins. PTEN's target protein however, was unknown.

Zhang discovered that SRC is a PTEN target. With its phosphate groups, SRC is active. PTEN stifles SRC by peeling away the phosphates.

If PTEN loss leads to Herceptin resistance, and PTEN targets SRC, would that make SRC the culprit?

On the trail of SRC

In a series of experiments the researchers found:

  • SRC is active in breast cancer cells once vulnerable but now resistant to Herceptin and in cells that are resistant from the start.
  • Activation of SRC drives resistance to Herceptin. Tumors with low SRC levels treated by Herceptin shrunk to 20 percent of their original volume in 21 days while SRC-heavy tumors increased by nearly 400 percent over the same time in mouse experiments.
  • SRC activity correlates with patient response to Herceptin. Assessing SRC activation in samples of 57 human breast cancer tumors, the team found that more than 90 percent of tumors with low SRC responded compared with 40 percent of tumors with active SRC.
  • Patients with little active SRC had a median survival of 57.9 months compared with 34.2 months in those with high SRC activity.
  • SRC is activated by a number of receptor tyrosine kinases that cause resistance, including IGF-1R, EGFR, ERBB2, HER3, and Met, separate pathways that work through SRC. "Block SRC, and you reverse them all," Zhang said.


Crushing resistance

Combining Herceptin and saracatinib to treat resistant tumors in mice reduced tumor volume by 90 percent in 25 days. Herceptin alone kept tumor volume about the same during the same period, while control and saracatinib alone permitted growth of more than 200 percent.

The difference was more striking in tumors deficient in SRC's enemy, the PTEN tumor-suppressor. The combination reduced tumor volume by more than 90 percent while the two drugs alone allowed growth of between 200 and 400 percent.

This study was funded by grants from the National Cancer Institute, MD Anderson Breast Specialized Program of Research Excellence; Department of Defense Center of Excellence; Susan G. Komen Breast Cancer Foundation Promise Grant; the Cancer Prevention and Research Institute of Texas, the MD Anderson Breast SPORE Career Development Award and Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Cancer 
8/20/14 
Novel Gene Predicts Both Breast Cancer Relapse And Response to Chemotherapy
By Biomedical Sciences Institutes (BMSI)
Singapore—Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors …
Cancer 
12/23/11 
UK Researchers Present Findings from Kentucky Breast Cancer Patients with Disease Relapse
By University of Kentucky
The University of Kentucky Markey Cancer Center breast oncologist Dr. Suleiman Massarweh and his research team presented findings from their studies on relapse of breast cancer at the San …
Cancer 
4/15/13 
An Important Discovery in Breast Cancer by IRCM Researchers
By Institut de recherches cliniques de Montreal
Montréal, April 15, 2013 – A team of researchers at the IRCM, led by Dr. Jean-François Côté, made an important discovery in breast cancer, which will published online this …
Journal 
12/17/12 
CWRU School of Medicine Researchers Discover New Molecule Linked to Late-stage Breast Cancer
By Case Western Reserve University
CLEVELAND -- Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive forms of breast cancer – a discovery that could point …
Cancer 
4/24/14 
★★ 
New Study Helps to Explain Why Breast Cancer Often Spreads to the Lung
By University of Western Ontario
New research led by Alison Allan, PhD, a scientist at Western University and the Lawson Health Research Institute, shows why breast cancer often spreads or metastasizes to the lung. …
Metastatic 
1/27/14 
Drug to Reverse Breast Cancer Spread in Development
By Cardiff University
Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells. The vast majority of deaths from cancer result from …
Cancer 
1/23/13 
Researchers Discover Promising Prognostic Marker for Aggressive Breast Cancer
By University Hospitals Case Medical Center
Cleveland - A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at …
Plexin-B1 
3/1/12 
Potential New Therapeutic Target for a Subset of Aggressive Breast Cancers
By Journal of Clinical Investigation
The main cause of death in women with breast cancer is spread of the original tumor to distant sites, a process known as metastasis. New therapeutic targets are urgently …
Breast 
8/3/11 
Research Explores How Breast Cancer Spreads And New Ways to Treat It
By US Department of Defense Congressionally Directed Medical Research Programs
ORLANDO, Fla. — August 3, 2011 — Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, …
Tumor 
3/30/11 
Interventional Radiologists Provide Hope in Delaying Growth, Spread of Breast Cancer
By Society of Interventional Radiology
CHICAGO, Ill. (March 29, 2011)—The growth and spread of breast cancer tumors may be delayed with a promising treatment that combines two innovative strategies: blocking the enzyme needed to …
Patients 
3/24/10 
What Should Be the Goal of Treatment in Metastatic Breast Cancer?
By ECCO-the European CanCer Organisation
Barcelona, Spain: Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over …
Tgen 
2/11/14 
TGen Study Uncovers Possible Genetic Markers in Breast Cancer That Spreads to the Brain
By The Translational Genomics Research Institute
PHOENIX, Ariz. — Feb. 10, 2014 — The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition
All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.